AG AGM Presentation Franois Martelet, CEO 22 22 June une 2015 - - PowerPoint PPT Presentation

AG AGM Presentation

François Martelet, CEO

22 22 June une 2015 2015

NetScientific ¡today

Fr François Martelet, M.D.

Jo Joined ned as as CE CEO in n June June 2015 2015

§ Degrees in Medicine, Legal Medicine and Business (France, USA)

Gl Global al bus usines ness exp exper erience ence in n big phar harma ma

§ Senior level commercial positions at Merck& Co, Inc. and Novartis Pharma, Schering-Plough and Eli Lilly

Bi Biotech ech / Bi Biophar harma ma exp exper erience ence

§ CEO at Avax Technologies Inc., a US biotech – therapeutic vaccines § CEO at Topotarget A/S European Biotech - oncology therapeutics § Senior advisor to CEO Stallergenes SA

3

Pu Pursuin ing a cle lear mis issio ion

Tr Transatlantic bi biomedi dical and d healthcare gr group p that funds ds and and dev evel elops techno echnologies es that hat offer er trans ansformat mative e be benefits to pe peopl ple’s lives and d so society ty

4

HQ London, ¡UK Listing AIM Symbol NSCI

• No. ¡of ¡Shares

35,902,020 Shareprice ¡(19/6/2015) £1.89 ¡ Market Cap ¡(19/6/2015) £67.9m

5

We Well qualified senior management team

Mi Michael Boyce-Ja Jaci cino, PhD He Head of US Investments & Operations Da David Gough, MBA He Head of EU Investments & Operations Vi Vijay Barathan, M.D. In Investment & Corporate Development Ma Mark Nanovich Fi Fina nanc nce e Direc ector Pe Peter Th Thomas FCA Ch Chief Financial Officer Er Ernest Schneider Ge General C Counsel & & C Company S Secretary

Fo Focused on healthcare

Fund Fund, d , develop and m manage early/mid-st stage healthcare te technology companies sourc rced fro rom stra trate tegic pa partnerships ps and d relationships ps in USA a and d Europe pe Pr Primary focus on Digital health, Diagnostics and and Therapeutics Rep Repres esent ent hi highl hly y at attract active ve grow

• wth

h mar market kets wher here e br breakthrough gh technology gy solutions are in high gh de demand

6

Po Portfolio lio

7

Di Diagnostics Th Therapeutics

De Delivering actionable information to patients to drive be behavioural change ge De Delivering cl clinica cal grade data for phys ysici cians to drive ve adoption Hi Highly specific tests to provide earlier diagnosis, increased mo monitoring ab ability an and ear arlier intervention Ne Next ge generation therapi pies

Di Digital health

Tr Transatlantic Source of opportunities

8

Wallace H. Coulter Foundation has partnered with sixteen university departments of biomedical

• engineering. Provides non-dilutive

funding for selected projects for commercialisation

WH WH Coulter Foundation Th Thiel Foundation In Institutions we work with

Peter Thiel’s foundation created Breakout Labs to support companies at the forefront of deep scientific innovation. Provides grant funding to select early-stage companies Lo Long-st standing relationsh ships s with leading rese searchers St Strateg egic partner nershi hip

Actions since January y 2015

Or Organisation of senior management te team

§ Mike Boyce-Jacino heads US operations § David Gough heads EU operations

Po Portfolio re revi view pro rocess comple lete ted & ra ratio tionalis isati tion in initi tiated

§ Focus on accelerating commercialisation and building value in core assets § Rationalisation of investments and technology opportunities

In Investec appointed as B Broker and N NOMAD Ne New br brandi ding g and d webs bsite Re Re-la launch of NetS tScie ienti tific at t th the Capita ital l Mark rkets ts Day CE CEO appointed

9

2015 2015

9

Lo Looki king ah ahead ad

Ne Next steps Q3/Q4

Re Review and d strengt gthen the orga ganization and d bo board Ac Accelerating top five companies towards commercialisation De Delivering g value enhancing g news flow across the gr group De Define clear value inflection po points for our major assets Ne Next update in inte terim rim re results ts mid id Sep Septem ember er

11 11

2015 2015

11 11